CTAS stock · ORMP stock

CTAS vs ORMP

Cintas Corporation (CTAS) versus Oramed Pharmaceuticals Inc (ORMP) — a side-by-side from cached financials, not a winner call.

Cintas Corporation (CTAS) is a specialty business services company listed on US.

Oramed Pharmaceuticals Inc (ORMP) is a biotechnology company listed on US.

Latest reported CTAS revenue for 2025-05-31 was $10.34B. Net income was $1.81B. Revenue was up 7.7% from 2024-05-31 to 2025-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.

Latest reported ORMP revenue for 2023-12-31 was $1.3M. Net income was $5.5M. Revenue was up 48.2% from 2022-12-31 to 2023-12-31. ORMP currently screens at market cap $87.2M.

CTAS currently screens at market cap $89.01B and trailing P/E 51.3. ORMP currently screens at market cap $87.2M.

Not investment advice. Open the CTAS and ORMP stock pages for the full models.

Not investment advice.

Popular Stock Comparisons